FDA Approves Sunovion’s Aptiom for Seizures Associated With Epilepsy

The Food and Drug Administration Nov. 8 approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy.

Aptiom is approved for the treatment of partial seizures, the most common type of seizure seen in people with epilepsy, the agency said. The drug is marketed by Marlborough, Mass.-based Sunovion Pharmaceuticals Inc.

“Some patients with epilepsy do not achieve satisfactory seizure control from existing treatments,” said Eric Bastings, acting director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “It is important we continue to make new treatment options available to patients.” ...